Reply letter to: Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase i oncology trial participant - Reply to Füssenich et al.: A new, simple and objective prognostic score for phase i cancer patients

摘要

We thank Olmos and colleagues for their comments. As highlighted in our discussion validation of the Nijmegen model was needed. Olmos and colleagues compared the Nijmegen score with the Royal Marsden Hospital (RMH) score, described by Arkenau and colleagues, using the data collected from the European Drug Development Network (EDDN) (not available online), a collaboration of 14 phase I centres in seven European countries.